Supernus Pharmaceuticals Inc (NASDAQ:SUPN) stock has reached a new 52-week high, touching $39.38 as the company continues to show robust performance in the pharmaceutical sector. According to ...
Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has approved an update for the label for Qelbree to ...
ROCKVILLE, Md. - Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company specializing in CNS diseases with an impressive 89% gross profit margin, has announced the FDA approval of a ...
Equities research analysts at Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) in a research report issued to clients and investors on Monday, ...
The updated labeling for Qelbree provides additional information on the pharmacodynamic profile of the drug. Findings show ...
ROCKVILLE, Md., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ...
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug Piper Sandler downgrades Supernus Pharmaceuticals due to slower-than-expected growth in ...
Short interest in Supernus Pharmaceuticals Inc (NASDAQ:SUPN) decreased during the last reporting period, falling from 6.64M to 6.20M. This put 17.19% of the company's publicly available shares short.
21d
If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the ...
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback